One down, six to go as AstraZeneca hands off Handa ANDA on Seroquel XR
This article was originally published in Scrip
Executive Summary
As part of a settlement agreement for one of its ongoing patent infringement litigation cases concerning Seroquel XR (quetiapine fumarate) extended-release tablets, AstraZeneca has granted Handa Pharmaceuticals a licence to enter the US market with a generic version of the drug, on 1 November 2016 or earlier upon certain circumstances.